CDSCO finds 50 common medicines substandard, including those for fever, blood pressure, diabetes, and acid reflux

In a recent survey conducted by the Central Drug Standards Control Organisation (CDSCO), over 50 drugs commonly prescribed for conditions like high blood pressure, acid reflux, and erectile dysfunction have been found to be of substandard quality. These drugs are currently being sold in the market despite not meeting the required safety and efficacy standards, a TOI report stated.

Drugs from leading companies under scrutiny

According to the data released last month, several batches of drugs manufactured by prominent pharmaceutical companies failed to meet CDSCO's quality standards. For instance, a specific batch of Pulmosil (Sildenafil injection), produced by Sun Pharmaceuticals, was flagged for being substandard. However, the company stated that the tainted batch was not produced by them and claimed it to be a spurious product. Similarly, another batch of Pantocid, a medication commonly used for acid reflux, was also found to be spurious.

Another leading manufacturer, Glenmark Pharmaceuticals, faced scrutiny for a batch of Telma H (Telmisartan 40mg and Hydrochlorothiazide 12.5mg tablets IP), which is used to treat high blood pressure. Glenmark also denied manufacturing the flagged batch. Additionally, a batch of Clavam 625 (Amoxicillin and Potassium Clavulanate tablets IP) produced by Alkem Health Science was found to be non-compliant with quality standards.

CDSCO clarifies on drug safety

A senior CDSCO official clarified, "The failure of any specific batch of a drug to meet the standards does not mean all drugs being sold by that name are substandard. Also, quality issues are monitored periodically and often addressed promptly to prevent any public health issues."

Regulatory measures to improve drug quality

CDSCO, as the regulatory body responsible for overseeing drug approvals and clinical trials, conducts regular random sampling of drugs to ensure compliance with Good Manufacturing Practices (GMP). Although there has not been a significant rise in substandard drug cases, officials emphasized that the government remains committed to improving manufacturing processes and ensuring adherence to quality standards.